Botanix Pharmaceuticals Ltd
BOT.ASXHealth Care
Pharmaceuticals.
Market Data
$0.024
+0.0%$62.9M
-100000.0x
$-0.047
0.00%
-0.9%
Latest Earnings
Correction - Appendix 4D
2 March 2026
Botanix Pharmaceuticals reported a significant correction to its H1 2025 revenue figure, which should have been $16.5M (not the prior typo'd amount), representing extraordinary 4,675% growth compared to H1 2024's $345,673. However, the company reported a net loss of $33.2M (vs $30.9M loss in H1 2024), reflecting heavy R&D and commercialization spending post-FDA approval of its lead product Sofdra, with no dividend declared. Key points: Revenue surged 4,675% to $16.5M in H1 2025 vs $345,673 in H1 2024, driven by FDA approval and commercialization of Sofdra (first new chemical entity approved for primary axillary hyperhidrosis); Loss narrowed to $33.2M from $30.9M in prior period despite massive revenue growth, indicating improving operational leverage; Net tangible assets per share improved to 1.39 cents (vs 2.71 cents prior period, partly reflecting capital structure changes or accounting adjustments)
Recent Announcements
Ceasing to be a substantial holder
Chester Asset Management Pty Ltd ceased to be a substantial holder of Botanix Pharmaceuticals Ltd (ASX: BOT) on 14 April 2026, with the previous substantial holder notice dated 26 March 2026. The notice references appendices for details of changes in relevant interests and associated persons.
Ceasing to be a substantial holder from IFL
IFL ceased to be a substantial holder.
Correction - Appendix 4D
Botanix Pharmaceuticals reported a significant correction to its H1 2025 revenue figure, which should have been $16.5M (not the prior typo'd amount), representing extraordinary 4,675% growth compared to H1 2024's $345,673. However, the company reported a net loss of $33.2M (vs $30.9M loss in H1 2024), reflecting heavy R&D and commercialization spending post-FDA approval of its lead product Sofdra, with no dividend declared. Key points: Revenue surged 4,675% to $16.5M in H1 2025 vs $345,673 in H1 2024, driven by FDA approval and commercialization of Sofdra (first new chemical entity approved for primary axillary hyperhidrosis); Loss narrowed to $33.2M from $30.9M in prior period despite massive revenue growth, indicating improving operational leverage; Net tangible assets per share improved to 1.39 cents (vs 2.71 cents prior period, partly reflecting capital structure changes or accounting adjustments)
Appendix 4D and Half Year Report
Botanix Pharmaceuticals reported H1 FY26 revenue of $16.5M, up 4,675% from $346k in the prior year, driven by Sofdra (sofpironium) ramp-up following FDA approval. However, the company posted a net loss of $33.2M (vs $30.9M loss in H1 FY25) as aggressive sales & marketing spend ($24.7M) and expanded sales force (to 50 professionals) offset early-stage revenue gains. The company raised $45M post-period end and is pursuing cost-of-goods negotiation with API suppliers for potential 25–40% COGS reduction. Key points: Revenue exploded 4,675% YoY to $16.5M as Sofdra sales ramp accelerated from minimal base; prescriptions shipped grew 171% to 45,769 in H1 FY26.; Sales force expanded to 50 credentialed professionals (from 27) with strong track records; market research shows 90% of HCPs expect to increase Sofdra prescribing in next six months.; Sofdra adherence rates 2.5x industry standard; fulfilment platform and SendRx pharmacy network delivering strong prior authorisation approval rates and improving gross-to-net yield (24% in Q2, targeting 30–40%).
Get real-time alerts for BOT
Receive AI-powered earnings summaries and instant notifications when Botanix Pharmaceuticals Ltd releases results.
Register Free